Long‐standing remission after 25‐OH D3 treatment in a case of chronic myelomonocytic leukaemia
- 1 December 1993
- journal article
- case report
- Published by Wiley in British Journal of Haematology
- Vol. 85 (4) , 811-812
- https://doi.org/10.1111/j.1365-2141.1993.tb03230.x
Abstract
This report describes a case of chronic myelomonocytic leukaemia (CMML) in whom a complete remission was achieved and sustained 15 months after treatment with 25-OH vitamin D3. No side-effects were observed. Although vitamin D1 has been used in the treatment of myelodysplastic syndromes, to our knowledge this is the first case of long-standing remission in a patient with CMML. This 'differentiation therapy' might be considered as a possible alternative in the management of this disease.Keywords
This publication has 5 references indexed in Scilit:
- Sustained haematological response to high-dose oral alfacalcidol in patients with myelodysplastic syndromesThe Lancet, 1992
- The Myelodysplastic Syndromes: Current Approaches to TherapyAnnals of Internal Medicine, 1990
- The Role of the Vitamin D Endocrine System in Health and DiseaseNew England Journal of Medicine, 1989
- 1,25‐DIHYDROXY‐VITAMIN D3 (1,25(OH)2D3) IN THE TREATMENT OF 1DIOPATHIC MYELOFIBROSISBritish Journal of Haematology, 1986
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982